HS PHARMACEUTICALS
HS Pharmaceuticals, LLC manufactures and distributes dermatological products for chronic wounds, burns, and drug resistant infections. The company offers its topical ointment under the Bensal HP brand name. HS Pharmaceuticals, LLC was founded in 2007 and is based in Greenville, South Carolina.
HS PHARMACEUTICALS
Industry:
Biotechnology Health Diagnostics Life Science Manufacturing
Founded:
2007-01-01
Address:
Greenville, South Carolina, United States
Country:
United States
Website Url:
http://www.hspharma.com
Total Employee:
1+
Status:
Active
Contact:
407-376-0417
Total Funding:
8.55 M USD
Technology used in webpage:
Microsoft Exchange Online Wix Wix DNS
Similar Organizations
BioAdvance
BioAdvance is a Pennsylvania-based venture capital firm that provides funding to life sciences startups.
Microdermis
Microdermis manufactures and markets skin care products for skin repair and protection, antimicrobial, and dental skin care.
Pacylex
Pacylex Pharmaceuticals develops a precision medicine solution for multiple common cancers.
Current Employees Featured
Founder
Official Site Inspections
http://www.hspharma.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.186
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "HS Pharmaceuticals"
Overview-Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Our innovative drugs on the market include: Saint Luolai (Pegmolesatide Injection）, the only marketed EPO Mimetic Peptide (EMP) worldwide; Ameile (aumolertinib mesylate tablets), …See details»
Company Information -Jiangsu Hansoh Pharmaceutical Group Co., …
Hansoh Pharma has always focused on corporate governance, corporate behavior, product safety and quality, access to healthcare, human resource development, environmental protection and …See details»
公司简介-翰森制药集团有限公司 - cn.hspharm.com
翰森制药集团有限公司是一家专注于常见恶性肿瘤领域的新药研发企业。See details»
公司簡介-翰森製藥繁體 - tc.hspharm.com
翰森製藥是中國領先的創新驅動型製藥公司，致力於通過持續創新改善人類健康，重點關注抗腫瘤、抗感染、中樞神經系統類疾病、代謝疾病及自身免疫性疾病等治療領域。See details»
公司简介-豪森药业 | 持续创新，提高人类生命质量
江苏豪森药业集团有限公司成立于1995年，是一家集药物研发、制造、销售为一体的创新驱动型制药企业，为翰森制药（03692.hk）的重要子公司，致力于通过持续创新提高人类生命质量，重 …See details»
Introduction_Jiangsu Hansyn Pharmaceutical Co., Ltd - hspharm.cn
Hansyn Pharma is a private high-tech pharmaceutical organization, with major share holders of ‘Hengchang Investment’ under Jiangsu Huachang Group, and ‘Winfast Holding’ in Nanjing, …See details»
公司简介-投资者关系-翰森制药集团有限公司
翰森制药是中国领先的创新驱动型制药公司，致力于通过持续创新改善人类健康，重点关注抗肿瘤、抗感染、中枢神经系统类疾病、代谢疾病及自身免疫性疾病等治疗领域。See details»
投資者關係-翰森製藥繁體 - tc.hspharm.com
翰森製藥是中國領先的創新驅動型製藥公司，致力於通過持續創新改善人類健康，重點關注抗腫瘤、抗感染、中樞神經系統類疾病、代謝疾病及自身免疫性疾病等治療領域。See details»
翰森制药集团—持续创新，提高人类生命质量-翰森制药集团有限公司
翰森制药是中国领先的创新驱动型制药企业，致力于通过持续创新改善人类健康与生命质量，重点关注抗肿瘤、抗感染、中枢神经系统类疾病、代谢疾病及自身免疫性疾病等领域。公司连续多 …See details»
Work with Us-Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Hansoh Pharma has always focused on corporate governance, corporate behavior, product safety and quality, access to healthcare, human resource development, environmental protection and …See details»
翰森製藥集團—持續創新，提高人類生命質量-翰森製藥繁體
翰森製藥集團已發展成為國內知名的創新型醫藥產業集團，國內抗腫瘤和精神類藥物研發生產領軍企業，國內最具創新力醫藥企業之一，國家高新技術企業、國家技術創新示範企業。See details»
Hansoh Bio - Overview, News & Similar companies | ZoomInfo.com
Hansoh Bio contact info: Phone number: (240) 751-6019 Website: www.hspharm.com What does Hansoh Bio do? Hansoh Bio is the U.S.based research & development subsidiary of Hansoh …See details»
投资者关系-翰森制药集团有限公司 - cn.hspharm.com
Jun 13, 2019 翰森制药是中国领先的创新驱动型制药公司，致力于通过持续创新改善人类健康，重点关注抗肿瘤、抗感染、中枢神经系统类疾病、代谢疾病及自身免疫性疾病等治疗领域。See details»
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Product quality talent development 68 7.1 r&d and innovation 71 7.2 product safety and quality 81 7.3 customer service 98 9.1 diversified talent team 102 9.2 talent cultivation and development …See details»
研发平台-翰森制药集团有限公司 - cn.hspharm.com
翰森制药始终聚焦未被满足的临床需求，不断探索生物科技前沿技术领域，通过基础创新、产品组合创新等形成全方位、多元化、差异化管线覆盖，利用优势技术平台，持续为患者研发创新优 …See details»
2024 ASCO Annual Meeting | Five Innovative Studies Sponsored …
Jun 7, 2024 The study involved collecting the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) and EORTC …See details»
翰森制药集团全球研发总部在上海开工建设-新闻发布-翰森制药集 …
Apr 1, 2024 2024年3月29日，作为 2024上海全球投资促进大会的系列活动之一，浦东产业生态场景合作发展大会的分会场， 翰森制药集团全球研发总部项目开工仪式在上海市浦东新区隆重 …See details»
2023 IDF | Hansoh Pharma Release the Phase 1 Study Data of the …
Dec 11, 2023 The IDF Virtual Congress 2023 will be held from December 4 to 7. Phase 1 study data from Hansoh Pharma’s HS-20094 (a novel dual GIP and GLP-1 receptor agonist) will be …See details»
翰森制药HS-20093（B7-H3 ADC）获国家药品监督管理局批准纳 …
2024年11月1日 . 翰森制药集团有限公司 (以下简称“翰森制药”，03692.hk)宣布，公司自主研发的b7-h3靶向抗体-药物偶联物（adc）注射用hs-20093获中国国家药品监督管理局（nmpa）药品 …See details»